tradingkey.logo
tradingkey.logo
Search

US FDA declines to approve Scholar Rock's muscle weakness drug

ReutersSep 23, 2025 11:04 AM
facebooktwitterlinkedin

- The U.S. Food and Drug Administration has declined to approve Scholar Rock's SRRK.O drug for a rare neuromuscular disease, citing issues at a third party manufacturing facility, the company said on Tuesday.

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Recommended Articles

Tradingkey
KeyAI